Video presentation of real-world research on the impact of upfront chemo choice on second-line immunotherapy in bladder cancer.
| CONTEXT: Lead author Benjamin Miron presents findings of a real-world study into the influence of 1st line chemotherapy on overall survival (OS) outcomes in patients with advanced urothelial carcinoma who received 2nd line immunotherapy in a 3 minute video. The results were shared at the ASCO Annual meeting 2021 and in the Journal of Clinical Oncol. READ TIME: <1 min 1. “Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.” 2. “Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a real-world study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on overall survival outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.” Source URL:https://www.urologytimes.com/view/dr-miron-on-impact-of-upfront-chemo-choice-on-second-line-immunotherapy-in-bladder-cancer  |